Patents Assigned to Pfizer Inc.
  • Cannabinoid receptor ligands and uses thereof
    Publication number: 20040157838
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
    Type: Application
    Filed: January 21, 2004
    Publication date: August 12, 2004
    Applicant: Pfizer Inc
    Inventor: David A. Griffith
  • PPAR activators
    Publication number: 20040157885
    Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
    Type: Application
    Filed: November 24, 2003
    Publication date: August 12, 2004
    Applicant: Pfizer Inc
    Inventors: Scott W. Bagley, Thomas A. Brandt, Robert W. Dugger, William A. Hada, Cheryl M. Hayward, Zhengyu Liu
  • Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
    Publication number: 20040157834
    Abstract: Compounds according to the formula A-Z-W as herein described, wherein A is selected from the groups consisting of: A′-(CH2)n—, A′-(CH2)nSO2—, and A′-(CH2)nCO—, where n is 0 to 4; and A═ is selected from
    Type: Application
    Filed: February 9, 2004
    Publication date: August 12, 2004
    Applicant: Pfizer Inc
    Inventors: Bruce A. Hay, Bridget M. Cole, Anthony P. Ricketts
  • Process for the production of quinazolines
    Publication number: 20040158062
    Abstract: The present invention relates to a novel process for producing quinazoline compounds which are useful in therapy. More specifically, the compounds are useful in the treatment of benign prostatic hyperplasia.
    Type: Application
    Filed: February 9, 2004
    Publication date: August 12, 2004
    Applicant: Pfizer Inc
    Inventors: Jens Bertil Ahman, Paul Blaise Hodgson, Sarah Jane Lewandowski, Robert Walton
  • Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
    Publication number: 20040157824
    Abstract: This invention provides a compound of the formula: 1
    Type: Application
    Filed: February 3, 2004
    Publication date: August 12, 2004
    Applicant: Pfizer Inc.
    Inventors: Kazuo Ando, Tomoki Kato, Akiyoshi Kawai, Tomomi Nonomura
  • N-(indole-2-carbonyl)-b-alaninamide crystal forms
    Publication number: 20040152758
    Abstract: The instant invention provides crystal forms of 5-chloro-N-[(1S,2R)-3-[3R,4S]-3,4-dihydroxy-1-pyrrolidinyl]-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide (I) 1
    Type: Application
    Filed: October 22, 2003
    Publication date: August 5, 2004
    Applicant: Pfizer Inc.
    Inventors: Douglas J. M. Allen, Frank R. Busch, Joseph F. Krzyzaniak, Zheng Jane Li, Susan L. Orrill, Peter R. Rose, Derek L. Tickner, Harry O. Tobiassen
  • Thiazole compounds for treatment of neurodegenerative disorders
    Publication number: 20040152747
    Abstract: The invention provides compounds of Formula I: 1
    Type: Application
    Filed: October 8, 2003
    Publication date: August 5, 2004
    Applicant: Pfizer Inc
    Inventors: Yuhpyng L. Chen, Michael L. Corman
  • Avermectin and praziquantel combination therapy
    Publication number: 20040151744
    Abstract: An antiparasitic combination therapy compising a combination of a 13-monosaccharide 5-oxime avermectin, such as selamectin, and praziquantel in a veterinarily acceptable carrier, diluent or adjuvant. Also provided is a method of treatment or prophylaxis of a parasitic infestation as well as a kit useful in the treatment or prophylaxis of a parasitic infestation of flea, heartworm or tapeworm in a mammal.
    Type: Application
    Filed: January 21, 2004
    Publication date: August 5, 2004
    Applicant: Pfizer Inc
    Inventor: Bernard Frank Bishop
  • Novel methods involving the determination of activity of enzymes that use or produce prostaglandin endoperoxide H2
    Publication number: 20040152148
    Abstract: The present invention provides assays for determining the activity of an enzyme that uses or produces prostaglandin endoperoxide H2 (PGH2), methods of using the assays to screen for potential modulators of such enzymes, and kits for practice of the assays.
    Type: Application
    Filed: January 23, 2004
    Publication date: August 5, 2004
    Applicant: Pfizer Inc
    Inventor: Ralph H. Lambalot
  • Isothiazole derivatives useful as anticancer agents
    Publication number: 20040152691
    Abstract: The invention relates to compounds of the formula 1 1
    Type: Application
    Filed: July 24, 2003
    Publication date: August 5, 2004
    Applicant: Pfizer Inc
    Inventors: Blaise Lippa, Tricia Ann Kwan, Joel Morris, Susan D. LaGreca, Matthew David Wessel
  • Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist
    Publication number: 20040152713
    Abstract: The present invention provides methods, pharmaceutical compositions and kits for treating joint pain and/or improving sleep using a SERM of formula (I): 1
    Type: Application
    Filed: January 21, 2004
    Publication date: August 5, 2004
    Applicant: Pfizer Inc.
    Inventor: Charles D. Petrie
  • Pharmaceutically active compounds
    Publication number: 20040152712
    Abstract: Compounds of the formula (1): 1
    Type: Application
    Filed: January 6, 2004
    Publication date: August 5, 2004
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Bunnage, Keith Michael DeVries, Laurence James Harris, Philip Charles Levett, John Paul Mathias, Joanna Teresa Negri, Stephen Derek Albert Street, Albert Shaw Wood
  • N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
    Patent number: 6770778
    Abstract: The present invention relates to oxygenated esters of 4-substituted-phenylamino benzhydroxamic acid derivatives, pharmaceutical compositions, and methods of use thereof.
    Type: Grant
    Filed: January 23, 2003
    Date of Patent: August 3, 2004
    Assignee: Pfizer Inc
    Inventors: Stephen Douglas Barrett, Michael David Kaufman, Gordon William Rewcastle, Julie Ann Spicer
  • Pharmaceutically active compounds
    Patent number: 6770645
    Abstract: Compound of general formula I: wherein R1, R2, R3, R4, X, Y and R5 have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: August 3, 2004
    Assignee: Pfizer Inc.
    Inventors: Stephen Martin Denton, Mark Ian Kemp, Sandra Dora Newman, David James Rawson
  • Attenuated forms of bovine viral diarrhea virus
    Publication number: 20040146854
    Abstract: The present invention relates to attenuated forms of bovine viral diarrhea (BVD) viruses. In particular, the present invention relates to attenuated BVD viruses made by mutating the Npro protease gene and inserting a bovine ubiquitin coding sequence. The attenuated viruses of the present invention can be used to raise antibodies against BVDV. Immunogenic compositions and vaccine compositions, as well as therapeutic and diagnosis methods, are also provided by the present invention.
    Type: Application
    Filed: November 21, 2001
    Publication date: July 29, 2004
    Applicant: Pfizer Inc.
    Inventors: Xuemei Cao, Gabriele M. Zybarth
  • Depot formulations in the form of a suspension
    Publication number: 20040146562
    Abstract: A pharmaceutical kit for preparing an injectable depot formulation of an aryl-heterocyclic pharmaceutical compound, such as ziprasidone, and a method of preparing said depot formulation is disclosed.
    Type: Application
    Filed: October 21, 2003
    Publication date: July 29, 2004
    Applicant: Pfizer Inc
    Inventor: Jaymin C. Shah
  • Isothiazole derivatives
    Publication number: 20040147574
    Abstract: Novel isothiazole compounds, including derivatives thereof, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, hyperproliferative disorders and fibrotic diseases.
    Type: Application
    Filed: January 26, 2004
    Publication date: July 29, 2004
    Applicant: Pfizer Inc
    Inventor: Michael J. Munchhof
  • Combination chemotherapy
    Publication number: 20040147478
    Abstract: This invention relates to a method for treating cancer utilizing a combination of known oncolytic agents. Specifically, this invention relates to a method for treating cancer utilizing a combination of a MEK inhibitor and capecitabine.
    Type: Application
    Filed: November 14, 2003
    Publication date: July 29, 2004
    Applicant: Pfizer Inc.
    Inventor: Ronald Lynn Merriman
  • Liquid conjugates of solid pharmaceuticals
    Publication number: 20040147532
    Abstract: A liquid phase conjugate formed of a bioactive agent such as a drug compound, e.g. ziprasidone, and a liquid polymer of requisite functionality is disclosed.
    Type: Application
    Filed: October 24, 2003
    Publication date: July 29, 2004
    Applicant: Pfizer Inc
    Inventors: Shalaby W. Shalaby, Jaymin C. Shah
  • Anti-IgE vaccines
    Publication number: 20040146504
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
    Type: Application
    Filed: January 5, 2004
    Publication date: July 29, 2004
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler